Sangamo Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Sangamo Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sangamo Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sangamo Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sangamo Therapeutics Inc (Sangamo) is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFP candidates are based on its proprietary gene therapy technologies. The ZFPs-based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and the production of transgenic animals. Sangamo's major products include gene therapies and genomic medicines targeting neurological disorders, autoimmune diseases, and oncology. The company also collaborates with other pharmaceutical companies to develop and commercialize its therapies. Sangamo is headquartered in Brisbane, California, the US.
Headquarters
United States of America
Address
501 Canal Blvd., Richmond, California, 94804
Website
www.sangamo.com
Telephone
1 510 9706000
No of Employees
142
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SGMO (OTC)
Revenue (2024)
$39.6M
-31.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-25.5%
(2024 vs 2023)
Market Cap*
$18.7M
Net Profit Margin (2024)
XYZ
-83.4%
(2024 vs 2023)
* As of and is in US$
Sangamo Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Sangamo |
| ST-503: Idiopathic small fiber neuropathy (iSFN) | ZFP Therapeutic |
| Prion Disease(ST-506) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Bankruptcy Filing | In June, the company filed for bankruptcy. |
| 2025 | Regulatory Approval | In December, the company received a grant designation from the U.S. Food and Drug Administration for ST-503, an investigational epigenetic regulator to treat intractable pain due to small fiber neuropathy, a type of chronic neuropathic pain. |
| 2025 | Contracts/Agreements | In April, the company signed a license agreement with Eli Lilly and Co, allowing it to leverage Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, and treat certain diseases of the central nervous system. |
Competitor Comparison
| Key Parameters | Sangamo Therapeutics Inc | GSK plc | Amgen Inc | Vertex Pharmaceuticals Inc | BioMarin Pharmaceutical Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | United States of America | United States of America | United States of America |
| City | Richmond | London | Thousand Oaks | Boston | San Rafael |
| State/Province | California | England | California | Massachusetts | California |
| No. of Employees | 142 | 66,841 | 31,500 | 6,400 | 3,221 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sandy Macrae | Chief Executive Officer; Director | Executive Board | - | - |
| Alexander D. Macrae, PhD | President; Chief Executive Officer; Director | Executive Board | 2016 | 62 |
| Scott B. Willoughby | Secretary; Chief Legal Officer | Senior Management | 2021 | 50 |
| Nathalie Dubois Stringfellow, PhD | Chief Development Officer | Senior Management | 2022 | 63 |
| Phillip Ramsey | Chief Technical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer